Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection
Condition: HIV
Intervention: Atazanavir; Atazanavir; Ritonavir; Ritonavir; Tenofovir (TDF); Tenofovir (TDF); Nucleoside Reverse Transcriptase Inhibitor (NRTI); Nucleoside Reverse Transcriptase Inhibitor (NRTI); Famotidine (FAM); Famotidine (FAM)
Intervention description: Capsule, oral, 300 mg, once daily, 10 days; Capsule, oral, 400 mg, once daily, 7 days; Capsule, oral, 100 mg, once daily, 10 days; Capsule, oral, 100 mg, once daily, 7 days; Capsule, oral, 300 mg, once daily, 10 days; Capsule, oral, 300 mg, once daily, 7 days; Oral, 10 days; Oral, 7 days; Tablet, oral, 20 mg, twice daily, 7 days; Tablet, oral, 40 mg, twice daily, 7 days
Intervention MeSH terms: Ritonavir; Atazanavir Sulfate; Tenofovir; Reverse Transcriptase Inhibitors; Famotidine
Phase: Phase 4
Study type: Interventional
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 25.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: No

Summary:

      The purpose of this study is to assess the effects of famotidine, given twice daily, on
      atazanavir administered with ritonavir and tenofovir in HIV-infected participants.
    

Eligibility criteria:

        Key inclusion criteria:

          -  Males and females, 18 to 65 years of age, with HIV infection and a body mass index of
             18.0 to 35.0 kg/m^2

          -  HIV-infected participants receiving a treatment regimen containing only
             atazanavir/ritonavir, 300/100 mg once daily (QD) + tenofovir, 300 mg QD + at least 1
             other nucleotide reverse transcriptase inhibitor continuously for at least 3 months
             prior to study day 1

          -  Plasma HIV RNA levels of <50 copies/mL and a CD4 count >200 cells/mm^3.

          -  No history of virologic failure on a protease inhibitor (PI), documented phenotypic PI
             resistance, or primary PI mutations, according to International AIDS Society
             recommendations

          -  No documented phenotypic resistance to atazanavir or primary genotypic mutations
             causing resistance to atazanavir

          -  Women of childbearing potential who were not nursing or pregnant and were using an
             acceptable method of contraception for at least 4 weeks before dosing, during the
             study, and for 8 weeks from the last dose of study drug.

          -  Women with a negative pregnancy test result within 24 hours prior to dosing with study
             medication

          -  Women not breastfeeding

          -  Men willing or able to agree to practice barrier contraception for the duration of the
             study and at least 3 months after dosing.

        Key exclusion criteria:

          -  Any history of CD4 cell count <50 cells/mm^3

          -  Previously documented phenotypic or genotypic resistance to any of the currently
             prescribed NRTIs

          -  Any significant acute illness within 6 months of study day 1 or chronic medical
             illness unless stable or controlled by a nonprohibited medication

          -  Any major surgery within 4 weeks of study day 1

          -  Any gastrointestinal surgery that could impact upon the absorption of any study drug

          -  Inability to be venipunctured and/or tolerate venous access

          -  History of Gilbert's syndrome, hemophilia, chronic pancreatitis, hypochlorhydria,
             achlorhydria, clinically relevant gastroesophageal reflux disease, hiatal hernia, or
             peptic/gastric ulcer disease

          -  Intractable diarrhea (≥ 6 loose stools/day for at least 7 consecutive days) within 30
             days prior to study day 1

          -  Recent (within 6 months prior to study day 1) drug or alcohol abuse

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, electrocardiogram (ECG)

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG, or clinical laboratory determinations, which
             would not be expected for the extent of HIV disease

          -  Any of the following on 12-lead ECG prior to dosing on study day 1, confirmed by
             repeat: PR ≥ 210 msec; QRS ≥ 120 msec; QT ≥ 500 msec; QTcF ≥ 450 msec

          -  Second- or third-degree A-V block or clinically relevant ECG abnormalities

          -  Positive urine screen for drugs of abuse at screening or prior to dosing without a
             valid prescription. Positive urine drug screen for cannabinoids with or without a
             prescription is not exclusionary

          -  Creatinine clearance, as estimated by method of Cockcroft and Gault, less than 60
             mL/min

          -  Liver enzyme levels > 3* the upper limit of normal (ULN) prior to dosing on study day
             1

          -  Total bilirubin level >10*ULN prior to study day 1

          -  Positive blood screen for hepatitis B surface antigen or hepatitis C antibody.